Clinical Trial Update: Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL [Phase 2]

View source ↗

Summary

Phase 2 trial update for rituximab, yttrium Y-90 ibritumomab tiuxetan in relapsed follicular non-Hodgkin lymphoma (stages II-IV).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituximab, Yttrium Y-90 ibritumomab tiuxetan

Snippet

Sponsor: University of Arizona | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2019-08-28